Abstract
This study was designed to compare the efficacy of cyclosporine ophthalmic emulsion 0.05% with an artificial tear solution for the treatment of rosacea-associated eyelid and corneal pathology. Double-masked, randomized, 3-month clinical trial of 37 patients with rosacea-associated eyelid and corneal changes (defined as lid margin telangiectasia, meibomian gland inspissation, and/or fullness of the lid margin). All findings were standardized and compared to photographs for grading. There was a statistically significant increase in Schirmer (with anesthesia) scores of 2.7±2.2 mm after 3 months of treatment in the topical cyclosporine group (PP=0.271) in the artificial tears group. The mean tear break-up time score significantly improved in the topical cyclosporine group (mean increase of 3.56±1.5 seconds, PP=0.929). The topical cyclosporine group exhibited a significantly greater mean reduction in corneal staining scores (−1.3±0.53) compared with the control group (−0.2±0.83; between groups PP=0.022). Limitations of the study included an older, predominantly Caucasian patient population and short trial length. Topical cyclosporine 0.05% is more effective than artificial tears for the treatment of rosacea-associated lid and corneal changes.

This publication has 17 references indexed in Scilit: